<DOC>
	<DOCNO>NCT01498952</DOCNO>
	<brief_summary>A Phase 1b/2 , open-label , randomize study evaluate MEDI-573 combination standard care adult subject unresectable metastatic HCC .</brief_summary>
	<brief_title>MEDI-573 Combination With SOC Unresectable Metastatic HCC .</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Age ≥ 18 year minimum age consent per local regulation time screen Unresectable metastatic hepatocellular carcinoma ECOG Performance Status ≤ 2 Life expectancy ≥ 3 month ; ChildPugh Score Cirrhosis Mortality &gt; 7 point Prior current system anticancer therapy HCC , include cytotoxic , biologic , target experimental therapy Prior local treatment HCC le 4 week prior initiate study treatment Active second malignancy Major surgery , open biopsy significant traumatic injury within 4 week prior initiate study treatment Thrombotic embolic event within 6 month prior initiate study treatment Ongoing pancreatitis Uncontrolled refractory ascites Evidence ongoing spinal cord compression , know carcinomatous meningitis , know leptomeningeal carcinomatosis Hepatic encephalopathy &gt; Grade 1 Active brain metastasis exception Poorly control diabetes mellitus Active coronary artery disease Uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>HCC , liver cancer , hepatocellular carcinoma , MEDI-573 , anti-IGF</keyword>
</DOC>